Exocrine Pancreas Carcinoma — Trials

Exocrine Pancreas Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 358
Recruiting: 209
Ph III recruiting: 23
Growth YoY: +41.4%
Industry share: 41%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (136)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07083479	Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma(AMPLIFY-EAP)	no longer available	—	—	Elicio TherapeuticsINDUSTRY	0	Jul 10, 2026	clinicaltrials
NCT07399015	Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC	no longer available	—	—	Endevica BioINDUSTRY	0	Feb 18, 2026